Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial
Article Sidebar
Main Article Content
Abstract
Background: Outpatient COVID-19 monoclonal antibody (mAb) treatment via subcutaneous delivery, if effective, overcomes the logistical burdens of intravenous administration.
Methods: ACTIV-2/A5401 was a randomized, masked placebo-controlled platform trial where participants with COVID-19 at low risk for progression were randomized 1:1 to subcutaneously administered BMS-986414 (C135-LS) 200 mg, plus BMS-986413 (C144-LS) 200 mg, (BMS mAbs), or placebo. Coprimary outcomes were time to symptom improvement through 28 days; nasopharyngeal SARS-CoV-2 RNA below the lower limit of quantification (LLoQ) on days 3, 7, or 14; and treatment-emergent grade 3 or higher adverse events (TEAEs) through 28 days.
Results: A total of 211 participants (105 BMS mAbs and 106 placebo) initiated study product. Time to symptom improvement favored the active therapy but was not significant (median 8 vs 10 days, P=0.19). There was no significant difference in the proportion with SARS-CoV-2 RNA <LLoQ at day 3 (risk ratio [RR] for BMS mAbs versus placebo: 1.03; 95%CI: 0.80, 1.32), at day 7 (RR: 1.04; 95%CI: 0.94, 1.15), or at day 14 (RR: 1.00; 95%CI: 0.90, 1.12). Fewer grade 3 TEAEs were reported for the BMS mAbs arm than placebo (RR: 0.58 [95%CI: 0.25, 1.32]). Through day 28, there were no deaths, and there were 4 hospitalizations in the BMS mAbs arm versus 3 in the placebo arm. Higher early plasma mAb concentrations were associated with more favorable outcomes.
Conclusions: While safe, the BMS mAbs delivered subcutaneously were not effective at treating COVID-19 at low risk for progression. The lack of clinically significant activity may relate to the pharmacokinetics of subcutaneous administration of mAbs.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Coronavirus Disease 2019 (COVID 19) Treatment Guidelines. National Institutes of Health. [Internet]2023 [cited August 15, 2023]. Available from: www.covid19treatmentguidelines.nih.gov/.
2. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C, Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Roque-Guerrero L, Acloque G, Aazami H, Cannon K, Simon-Campos JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Trial I. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. New Eng J Med. 2021;385(23):e81. doi: 10.1056/NEJMoa2108163. PubMed PMID: 34587383; PMCID: PMC8522800.
3. Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, Sarkis E, Solis J, Zheng H, Scott N, Cathcart AL, Hebner CM, Sager J, Mogalian E, Tipple C, Peppercorn A, Alexander E, Pang PS, Free A, Brinson C, Aldinger M, Shapiro AE, Investigators C-I. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. New Eng J Med. 2021;385(21):1941-50. doi: 10.1056/NEJMoa2107934. PubMed PMID: 34706189.
4. Belote A, Reece S, Robinson S, Jensen H, CarlLee S, Clark M, Parnell S, Geels C, Newton J. Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting. Monoclon Antib Immunodiagn Immunother. 2022;41(4):210-3. doi: 10.1089/mab.2022.0008. PubMed PMID: 35920868.
5. McCreary EK, Bariola JR, Wadas RJ, Shovel JA, Wisniewski MK, Adam M, Albin D, Minnier T, Schmidhofer M, Meyers R, Marroquin OC, Collins K, Garrard W, Berry LR, Berry S, Crawford AM, McGlothlin A, Linstrum K, Nakayama A, Montgomery SK, Snyder GM, Yealy DM, Angus DC, Kip PL, Seymour CW, Huang DT, Kip KE. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19. JAMA Netw Open. 2022;5(4):e226920. doi: 10.1001/jamanetworkopen.2022.6920. PubMed PMID: 35412625; PMCID: PMC9006104.
6. U.S. Food and Drug Administration: Fact Sheet for healthcare providers emergency use authorization (EUA) of REGEN-COVTM (casirivimab and imdevimab). [Accessed August 15, 2023] . Available from : https://www.regeneron.com/downloads/treatment-covid19-eua-fact-sheet-for-hcp.pdf2020.
7. Wu EL, Kumar RN, Moore WJ, Hall GT, Vysniauskaite I, Kim KA, Angarone MP, Stosor V, Ison MG, Bba AF, Achenbach CJ, Gates KL. Disparities in COVID-19 Monoclonal Antibody Delivery: a Retrospective Cohort Study. J Gen Intern Med. 2022;37(10):2505-13. doi: 10.1007/s11606-022-07603-4. PubMed PMID: 35469360; PMCID: PMC9037582.
8. Wiltz JL, Feehan AK, Molinari NM, Ladva CN, Truman BI, Hall J, Block JP, Rasmussen SA, Denson JL, Trick WE, Weiner MG, Koumans E, Gundlapalli A, Carton TW, Boehmer TK. Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 - United States, March 2020-August 2021. MMWR Morb Mortal Wkly Rep. 2022;71(3):96-102. doi: 10.15585/mmwr.mm7103e1. PubMed PMID: 35051133; PMCID: PMC8774154.
9. Wood DA, Aleem A, Davis D. Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas. StatPearls. Treasure Island (FL): StatPearls Publishing; Copyright © 2022, StatPearls Publishing LLC.; 2022.
10. Tulledge-Scheitel S, Bell SJ, Larsen JJ, Bierle DM, Takahashi P, Moehnke DE, Destro Borgen MJ, Springer DJ, Reinschmidt KJ, Baumbach LJ, Matoush JA, Heyliger A, Hanson SN, Razonable RR, Ganesh R. A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities. J Am Geriatr Soc. 2021;69(4):868-73. doi: 10.1111/jgs.17090. PubMed PMID: 33619724; PMCID: PMC8013486.
11. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, Gazumyan A, Finkin S, Hagglof T, Oliveira TY, Viant C, Hurley A, Hoffmann HH, Millard KG, Kost RG, Cipolla M, Gordon K, Bianchini F, Chen ST, Ramos V, Patel R, Dizon J, Shimeliovich I, Mendoza P, Hartweger H, Nogueira L, Pack M, Horowitz J, Schmidt F, Weisblum Y, Michailidis E, Ashbrook AW, Waltari E, Pak JE, Huey-Tubman KE, Koranda N, Hoffman PR, West AP, Jr., Rice CM, Hatziioannou T, Bjorkman PJ, Bieniasz PD, Caskey M, Nussenzweig MC. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437-42. doi: 10.1038/s41586-020-2456-9. PubMed PMID: 32555388; PMCID: PMC7442695.
12. Rockefeller University. Investigator’s Brochure: C135-LS/C144-LS Two Neutralizing Human Monoclonal Antibodies Targeting SARS CoV-2 S Protein Receptor Binding Domain. In: Squibb B-M, editor. 2021.
13. Schaefer-Babajew D, Wang Z, Muecksch F, Cho A, Loewe M, Cipolla M, Raspe R, Johnson B, Canis M, DaSilva J, Ramos V, Turroja M, Millard KG, Schmidt F, Witte L, Dizon J, Shimeliovich I, Yao KH, Oliveira TY, Gazumyan A, Gaebler C, Bieniasz PD, Hatziioannou T, Caskey M, Nussenzweig MC. Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. Nature. 2023;613(7945):735-42. doi: 10.1038/s41586-022-05609-w. PubMed PMID: 36473496; PMCID: PMC9876794.
14. Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs R, Ritz J, Giganti M, Javan AC, Li Y, Malvestutto C, Klekotka P, Price K, Nirula A, Fischer W, Bala V, Ribeiro RM, Perelson AS, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM, Team A-AS. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial. medRxiv : the preprint server for health sciences. 2021. doi: 10.1101/2021.12.17.21268009. PubMed PMID: 34981077; PMCID: PMC8722620.
15. Evering TH, Chew KW, Giganti MJ, Moser C, Pinilla M, Wohl DA, Currier JS, Eron JJ, Javan AC, Bender Ignacio R, Margolis D, Zhu Q, Ma J, Zhong L, Yan L, D’Andrea Nores U, Hoover K, Mocherla B, Choudhary MC, Deo R, Ritz J, Fischer WA, Fletcher CV, Li JZ, Hughes MD, Smith D, Daar ES, Team A-AS. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19. Ann Intern Med. 2023;176(5):658-66. doi: 10.7326/M22-3428. PubMed PMID: 37068272; PMCID: PMC10150320.
16. Bender Ignacio RA, Chew KW, Moser C, Currier JS, Eron JJ, Javan AC, Giganti MJ, Aga E, Gibbs M, Tchouakam Kouekam H, Johnsson E, Esser MT, Hoover K, Neytman G, Newell M, Daar ES, Fischer W, Fletcher CV, Li JZ, Greninger AL, Coombs RW, Hughes MD, Smith D, Wohl DA, Accelerating C-TI, Vaccines AST. Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials. JAMA Netw Open. 2023;6(4):e2310039. doi: 10.1001/jamanetworkopen.2023.10039. PubMed PMID: 37099295; PMCID: PMC10134004.
17. Taiwo BO, Chew KW, Moser C, Wohl DA, Daar ES, Li JZ, Greninger AL, Bausch C, Luke T, Hoover K, Neytman G, Giganti MJ, Olefsky M, Javan AC, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM, Team A-AS. Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19. J Infect Dis. 2023;228(2):133-42. doi: 10.1093/infdis/jiad013. PubMed PMID: 36661240; PMCID: PMC10345463.
18. Jilg N, Chew KW, Giganti MJ, Daar ES, Wohl DA, Javan AC, Kantor A, Moser C, Coombs RW, Neytman G, Hoover K, Jana A, Hart PA, Greninger AL, Szurgot B, Eron JJ, Currier JS, Hughes MD, Smith DM, Li JZ, Team A-AS. One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial. Clin Infect Dis. 2023;77(7):941-9. doi: 10.1093/cid/ciad342. PubMed PMID: 37279602; PMCID: PMC10552586.
19. Currier JS, Moser C, Eron JJ, Chew KW, Smith DM, Javan AC, Wohl DA, Daar ES, Hughes MD, Team A-AS. ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients. J Infect Dis. 2023;228(Suppl 2):S77-S82. doi: 10.1093/infdis/jiad246. PubMed PMID: 37650231; PMCID: PMC10469341.
20. Moser CB, Chew KW, Ritz J, Newell M, Javan AC, Eron JJ, Daar ES, Wohl DA, Currier JS, Smith DM, Hughes MD, Team A-AS. Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial. J Infect Dis. 2023;228(Suppl 2):S92-S100. doi: 10.1093/infdis/jiad209. PubMed PMID: 37650234; PMCID: PMC10686688.
21. Moser CB, Chew KW, Giganti MJ, Li JZ, Aga E, Ritz J, Greninger AL, Javan AC, Bender Ignacio R, Daar ES, Wohl DA, Currier JS, Eron JJ, Smith DM, Hughes MD, Team A-AS. Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials. J Infect Dis. 2023;228(Suppl 2):S101-S10. doi: 10.1093/infdis/jiad285. PubMed PMID: 37650235; PMCID: PMC10469328.
22. Wu Y, Guo Z, Yuan J, Cao G, Wang Y, Gao P, Liu J, Liu M. Duration of viable virus shedding and polymerase chain reaction positivity of the SARS-CoV-2 Omicron variant in the upper respiratory tract: a systematic review and meta-analysis. Int J Infect Dis. 2023;129:228-35. doi: 10.1016/j.ijid.2023.02.011. PubMed PMID: 36804640; PMCID: PMC9937726.
23. Garcia-Knight M, Anglin K, Tassetto M, Lu S, Zhang A, Goldberg SA, Catching A, Davidson MC, Shak JR, Romero M, Pineda-Ramirez J, Diaz-Sanchez R, Rugart P, Donohue K, Massachi J, Sans HM, Djomaleu M, Mathur S, Servellita V, McIlwain D, Gaudiliere B, Chen J, Martinez EO, Tavs JM, Bronstone G, Weiss J, Watson JT, Briggs-Hagen M, Abedi GR, Rutherford GW, Deeks SG, Chiu C, Saydah S, Peluso MJ, Midgley CM, Martin JN, Andino R, Kelly JD. Infectious viral shedding of SARS-CoV-2 Delta following vaccination: A longitudinal cohort study. PLoS Pathog. 2022;18(9):e1010802. doi: 10.1371/journal.ppat.1010802. PubMed PMID: 36095030; PMCID: PMC9499220.
24. Magyarics Z, Leslie F, Bartko J, Rouha H, Luperchio S, Schorgenhofer C, Schwameis M, Derhaschnig U, Lagler H, Stiebellehner L, Firbas C, Weber S, Campanaro E, Jilma B, Nagy E, Stevens C. Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers. Antimicrob Agents Chemother. 2019;63(8):10.1128/aac.00350-19. doi: 10.1128/AAC.00350-19. PubMed PMID: 31138568; PMCID: PMC6658777.